<DOC>
	<DOCNO>NCT00019994</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Phase II trial study effectiveness vaccine therapy treat patient metastatic melanoma respond previous therapy .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical response immunization use gp100:44-59 antigen peptide plus gp100:209-217 ( 210M ) MART-1:26-35 ( 27L ) antigen peptide patient metastatic melanoma HLA-DRB1*0401 HLA-A0201 positive . - Determine clinical response immunization use gp100:44-59 antigen peptide alone patient metastatic melanoma HLA-DRB1*0401 positive HLA-A0201 negative . - Determine immunologic response patient treat regimen measure change T-cell precursor treatment . - Evaluate toxicity profile regimens patient . OUTLINE : Patients assign one three immunization group base HLA-A0201 status prior gp100:209-217 ( 210M ) antigen peptide immunization : - Group 1 ( HLA-A0201 positive prior gp100:209-217 [ 210M ] antigen peptide ) : Patients receive gp100:44-59 gp100:209-217 ( 210M ) antigen peptide emulsify together Montanide ISA-51 ( ISA-51 ) subcutaneously ( SC ) gp100:44-59 MART-1:26-35 ( 27L ) antigen peptide emulsify together ISA-51 SC . - Group 2 ( HLA-A0201 positive prior gp100:209-217 [ 210M ] antigen peptide ) : Patients receive treatment group 1 . - Group 3 ( HLA-A0201 negative prior gp100:209-217 [ 210M ] antigen peptide ) : Patients receive gp100:44-59 antigen peptide emulsify ISA-51 SC alone . - All group : Treatment repeat every 3 week 4 dos absence disease progression unacceptable toxicity . Patients complete response 4 dos receive maximum 2 additional dos . Patients stable disease minor , mixed , partial response 4 dos receive maximum 12 additional dos . Patients response 4 dos receive immunization peptide interleukin-2 IV 15 minute every 8 hour maximum 12 dos begin 1 day immunization . Patients follow 3-4 week . PROJECTED ACCRUAL : A total 45-75 patient ( 15-25 per immunization group ) accrue study within 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic melanoma fail standard treatment HLADRB1*0401 positive Known HLAA0201 status PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 90,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL AST ALT less 3 time normal Hepatitis B surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No symptomatic cardiac disease Immunologic : No autoimmune disease No primary secondary immunodeficiency disease HIV negative Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active systemic infection PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunization entire gp100 molecule At least 3 week since prior gp100:209217 antigen peptide At least 3 week since prior biologic therapy Chemotherapy : At least 3 week since prior chemotherapy Endocrine therapy : At least 3 week since prior endocrine therapy No concurrent steroid therapy Radiotherapy : At least 3 week since prior radiotherapy Surgery : Prior surgery cancer allow Other : At least 3 week since prior therapy except surgery cancer</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>